Alcon and several pharmaceutical companies have entered a drug pricing agreement with the White House.
The participating drug makers committed to investing at least $19.6 billion in US manufacturing in the near term.
Specific pricing terms for Alcon remain undisclosed. These federal agreements typically function as part of broader government efforts to control healthcare costs.